NCT06260033
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 29, 2026 to Oct 29, 2027
- Notable Eligibility criteria expanded, about 26 words
- Secondary endpoints: details revised at 4 of 5 entries
- Study description revised
- Minor Start date changed from estimate of Sep 11, 2024 to Jul 23, 2024v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Dec 11, 2025 to Oct 29, 2026
- Start date: Jun 11, 2024 to Sep 11, 2024
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients currently taking SERMs/ SERDs immediately undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. Patients not currently taking SERMs/SERDs first receive F-FES IV and undergo PET/CT scans at baseline. After baseline FES PET/CT, patients with ≤ 4 sites of progressive disease then undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. All patients undergo FES PET/CT at 12 and 24 weeks. Patients with SD after 12 or 24 week FES PET/CT may continue standard systemic therapy. Patients with ≤ 4 sites of progressive disease after 12 or 24 week FES PET/CT may receive SBRT to additional sites in the absence of unacceptable toxicity or evidence of \> 4 sites of disease progression. All patients also undergo CT, PET/CT, or bone scans, and blood samples collection during screening and on study.
Procedures: Biospecimen Collection, Bone Scan, Computed Tomography, Positron Emission Tomography
Drugs: F-18 16 Alpha-Fluoroestradiol
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy
Sites
2 sites in 1 country